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Abstract 
Neuroendocrine tumors (NETs) possess unique features including expression of peptide 
hormone receptors as well as the capacity to concentrate and take up precursor forms of 
amines and peptides making hormones that are stored in secretory granules within the tumor 
cells (APUD). The expression of somatostatin receptors on tumor cells have been widely 
explored during the last two decades starting with 
111In-DTPA-Octreotide as an imaging agent 
followed  by 
68Ga-DOTATOC/TATE  positron  emission  tomography  scanning.  The  new 
generation  of  treatment  includes 
90Yttrium-DOTATOC/DOTATATE  as  well  as 
177Lutetium-DOTATOC/DOTATATE/DOTANOC treatment of various subtypes of NETs. 
The objective response rate by these types of PRRT is in the range of 30-45% objective re-
sponses with 5-10% grade 3/4 toxicity mainly hematologic and renal toxicity. The APUD 
mechanism is another unique feature of NETs which have generated an interest over the last 
two  decades  to  develop  specific  tracers  including 
11C-5HTP, 
18F-DOPA  and 
11C-hydroxyefedrin. These radioactive tracers have been developed in centres with specific 
interest in NETs and are not available everywhere. 
111In-DTPA-Octreotide is still the working 
horse in diagnosis and staging of metastatic NETs, but will in the future be replaced by 
68Ga-DOTATOC/DOTATATE PET/CT scanning which provide higher sensitivity and speci-
ficity and is also more convenient for the patient because it is a one-stop-procedure. Both 
90Yttrium-DOTATOC/DOTATATE  as  well  as 
177Lutetium-DOTATOC/DOTATATE  are 
important new therapies for malignant metastatic NETs. However, the precise role in the 
treatment algorithm has to be determined in forthcoming randomized trials. 
Key  words:  PRRT,  theranostics,  111In-DTPA-Octreotide,  68Ga-DOTATOC/TATE, 
90Yttrium-DOTATOC, 177Lutetium-DOTATOC/DOTATATE 
Background
Neuroendocrine  tumors  (NETs)  are  a  diverse 
group  of  malignancies  deriving  from  the  diffuse 
neuroendocrine  cell  system  with  localisation  almost 
everywhere in the  human body. The  most frequent 
localisations are in the lung, pancreas and small in-
testine.  However,  NETs  can  be  found  in  the  heart, 
middle  ear,  kidneys  and  ovaries.  The  incidence  of 
NETs has constantly increased over the last decade, 
being  now  about  6/100,000  with  a  prevalence  of 
35/100,000.[1] The tumors are heterogeneous in terms 
of clinical presentation and growth. Some of them are 
so called functioning tumors which means that they 
produce  peptide  or  amines  that  can  cause  distinct 
clinical symptoms such as flushing, diarrhea, hypo-
glycaemia,  gastric  ulcers  or  skin  rash.  The  largest 
group is however non-functioning tumors and usu-
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ally present with a large mass or bleeding and some-
times difficult to delineate from a classical cancer.[2] 
A unique feature of NET is the APUD characteristics 
which means that they concentrate and take up amino 
acids and precursors and produce hormones that are 
stored in secretory  granules within the tumor cells. 
These hormones and amines are then released into the 
circulations or to adjacent or even into gut lumen to 
regulate the different physiological processes in the 
body.[3] This APUD characteristic is also the bases for 
the development of specific molecular imaging pro-
cedures using tracers that will accumulate on the ba-
ses of uptake in the tumor cells by the so called APUD 
mechanism.  Another  unique  feature  of  NETs  is  the 
expression  of  different  receptors  on  the  tumor  cells 
not  only  typical  growth  regulating  factor  receptors 
such  as  VEGF,  IGF,  EGF  and  so  forth,  but  peptide 
hormone receptors such as somatostatin receptors as 
well as CCK receptors, GRP receptors and so forth. 
These  receptors  can  be  targeted  with  radiolabeled 
peptides for imaging and treatment.[4] 
 A  theranostic  system  integrates  some  form  of 
diagnostic testing to determine the presence of mo-
lecular targets for which a specific compound is in-
tended.  Molecular  imaging  serves  these  diagnostic 
functions  and  provides  powerful  means  for 
non-invasively detecting disease. The term molecular 
is  meant  to  describe  active  targeting  of  a  specific 
mechanism important in a particular disease process. 
The  reasons  for  a  tremendous  excitement  of 
theranostics is its revolutionary approach that prom-
ises improved therapy selection on the bases on spe-
cific molecular features of disease, greater predictive 
power for adverse effects and new ways to objectively 
monitor  therapy  response.[5]  Currently  molecular 
imaging  in  the  form  of  PET  with  18Fluoro  labelled 
glucose analog, 68Ga-DOTA-Octreotate and 11C-5HTP 
PET  has  revolutionised  the  clinical  management  in 
oncology and particular in the field of NETs. The di-
agnostic  accuracy  has  been  further  refined  by  the 
technical combination with anatomic imaging in the 
form of PET/CT as well as most recently PET/MRI. 
The current paper will concentrate on molecular im-
aging in NETs using somatostatin receptor scintigra-
phy  as  well  as  PET-scanning  with  specific  isotopes 
such  68Ga-DOTA-Octreotate,  18Fluoro-DOPA, 
5-Hydroxytryptophan (11C-5HTP). It will also discuss 
the powerful treatment of NETs with radioactive so-
matostatin compound such as  111In-DTPA-octreotide 
177Lutetium-DOTATATE  and  90Yttrium-DOTATOC 
for treatment of malignant NETs. 
Nuclear Medicine Imaging 
Somatostatin Receptor Scintigraphy (SRS) 
Somatostatin  receptors  are  G-protein  coupled 
membrane glycoproteins at the moment five subtypes 
of human somatostatin receptors have been cloned.[4] 
The  somatostatin  analogs  octreotide  and  lanreotide 
bind with high affinity to receptor subtypes 2 and 5. 
The  expression  of  somatostatin  receptor  type  2  is 
present in 70-90% of NETs. Therefore radioactive la-
belled  somatostatin  analogs  allow  the  visualisation 
and staging of these tumors expressing somatostatin 
receptors  2  and  5.  The  most  commonly  used  radi-
oligand is 111In-DTPA-octreotide (Octreoscan) recent-
ly co-registration with CT has been implemented in 
nuclear medicine.[6-8] This new fusion technique al-
lows better interpretation of the imaging finding with 
better anatomical localisation (Figure 1).  
 
Figure 1. Functioning imaging of neuroendocrine tumors using [111In]DTPA-octreotide (SPECT) and CT scanning from a patient with a 
malignant metastatic pancreatic endocrine tumor. Theranostics 2012, 2(5) 
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The  usual  dose  for  somatostatin  receptor  scin-
tigraphy (SRS) is 200 MBq of  111In-DTPA-octreotide. 
Planar  images  are  obtained  with  a  double  headed, 
large  field  of  view,  gamma  camera  equipped  with 
medium-energy  parallel-hole  collimators.  If 
whole-body acquisition is used, the scan speed should 
not exceed 3–5 cm/minute. Using a higher scan speed 
may result in failure to recognise small somatostatin 
receptor positive lesions and lesions with a low den-
sity of somatostatin receptors. Single photon emission 
tomography–computed  tomography  (SPECT)  may 
increase the sensitivity of detecting somatostatin re-
ceptor positive tissues and give a better anatomical 
localisation  than  planar  views.  Nowadays  SPECT 
images  are  obtained  using  a  triple-headed  camera. 
Because  of  its  relatively  long  half-life 
111In-DTPA-octreotide can be used to visualise recep-
tor-bearing tumors efficiently after 24 and 48 hours, 
by which times interfering background radioactivity 
has  been  reduced  by  renal  clearance.  Planar  aspect 
studies are therefore preferably performed 24 hours 
after  injection  of  the  radiopharmaceutical.  Repeat 
scintigraphy  after  48  hours  is  especially  indicated 
when the 24 hours image shows accumulation in the 
abdomen,  which  may  represent  radioactive  bowel 
content.[8] The question arises whether somatostatin 
analog therapy can be administered during SRS as the 
uptake  of  111In-DTPA-octreotide  in  somatostatin  re-
ceptor positive tumors and the spleen will be dimin-
ished due to blocking of the receptor by ‘cold’ soma-
tostatin analog. However, in our experience the ma-
jority of carcinoid tumors as well as pancreatic NETs 
are visualised during treatment with octreotide, alt-
hough  the  uptake  might  be  reduced.  We  therefore 
recommend  withdrawal  of  the  octreotide  immedi-
ate-release formulation 48 hours before undertaking 
scintigraphy.  Furthermore,  during  treatment  with  a 
long-acting somatostatin analog, scintigraphy should 
be performed just before the next injection. 
The sensitivity of SRS for detecting midgut car-
cinoid tumors has been reported in various studies to 
be somewhere between 80% and 100%. There is no 
significant difference in the results for foregut, midgut 
and hindgut NETs. Scintigraphy also provides a more 
accurate staging of disease by demonstrating tumor 
size that can not be shown by conventional imaging. 
SRS might also indicate the amount of somatostatin 
receptors, which may have bearing on the efficacy of 
treatment  with  somatostatin  analogs  (PRRT).  How-
ever, it must be pointed out that there is no complete 
concordance  between  SRS  results  and  the  receptor 
content  determined  by  immunohistochemistry  of 
tumor specimens. Gastrin-producing tumors express 
a large number of high-affinity somatostatin receptors 
type 2. The sensitivity of SRS in this case is about 80% 
and  is  the  recommend  staging  procedure  for  these 
tumors.[9] Insulin-producing tumors, particularly the 
benign ones do not express somatostatin receptor type 
2 and only about 50% of malignant insulin producing 
tumor  express  somatostatin  receptor  type  2.  Other 
neuroendocrine  pancreatic  tumors,  such  as  glu-
cagonomas and VIPomas, express type 2 somatostatin 
receptors  in  about  60–70%  of  patients.[10]  Thyroid 
medullary carcinomas and pheochromocytomas also 
express somatostatin receptors type 2 in about 40–60% 
of patients. Medullary thyroid carcinomas more often 
express type 1 receptors, and might therefore not be 
visualised by SRS. However, for both medullary thy-
roid  carcinomas  and  pheochromocytomas  there  are 
other  scanning  procedures,  such  as  PET-scanning, 
that might replace SRS. SRS is still the gold standard 
for diagnosis, localisation and staging of NETs.  
Positron emission tomography (PET) 
NETs  not  only  express  somatostatin  receptors 
but endocrine tumors cells take up hormone precur-
sor,  express  receptors  and  transporters  and  synthe-
size, store and release hormones.[3] Based on the so 
called amine precursor uptake and the decarboxyla-
tion’  (APUD)  concept,  tracers  such  as 
11C-5-hydroxytryoptophan and  11C-dihydroxypheny-
lalanine have been developed for the localisation of 
neuroendocrine  tumors  and  18F  6-fluorodopamine 
and  11C-hydroxyephedrine  for  the  localisation  of 
pheochromocytomas. Current tracers that are used for 
detection  and  follow-up  of  patients  with  NETs  are 
listed in table 1.  
 
Table 1. Specific Isotopes for NETs 
11C-5HTP (hydroxytryptophan) 
11C-Dopamine 
18F-Dopamine 
68Ga-DOTA-octreotide 
99Tc EDDA-HYNIC-octreotide 
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 (GLP-1) 
 
 
Positron emission tomography is a non-invasive 
technique for measurement of regional accumulation 
and quantification  of radioactive substances.  A bio-
logical substance can be labelled with radionuclides, 
such as  11C,  15O and  18F with emission of positrons. 
The positrons generate photons which are detected by 
a  special  camera.  The  half  life  of  standard  positron Theranostics 2012, 2(5) 
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emitters is as follows: 18F-110 minutes, 11C-20 minutes, 
15O-2 minutes. The most recent PET-scanners provide 
2.5 mm slices with a resolution of approximately 5.5 
mm. 
The ability to tag somatostatin analogs with 68Ga 
has revolutionized the role of PET in diagnosis, stag-
ing and therapy monitoring of patients with receptor 
positive  NETs.  One  of  the  advantages  of  the 
68Ga-DOTANOC/DOTATOC PET or PET/CT study 
over  111In-Octreotide scintigraphy is better visualisa-
tion of lesions which are difficult to be seen on planar 
or SPECT imaging.[11-13]  68Ga- DOTATOC PET ap-
pears to be superior especially in detecting small tu-
mors  or  tumors  bearing  only  low  density  of  SRS 
(Figure 2). In general 68Ga-DOTATOC or DOTANOC 
PET is able to pick up many lesions which could not 
be picked up by CT-scan. It is of significance in ther-
apy monitoring and is a useful adjunct in deciding the 
amount of radioactivity to be administered for PRRT. 
In an intraindividual study comparing the diagnostic 
efficacy  of  68Ga-DOTANOC  and  68Ga-DOTATATE, 
68Ga-DOTANOC  is  superior  to  68Ga-DOTATATE  in 
terms of sensitivity.[14] In summary, among several 
advantages  of  68Ga-somatostatin  analogs  over 
111In-DTPA Octreotide scintigraphy higher sensitivity 
is present.[15] It is a one-stop procedure, the patient 
can  leave  the  clinic  after  1  hour  instead  of  coming 
back 4 and 24 hours for scanning. It will also in the 
future be cheaper than SRS. 
 
 
Figure 2.  68Ga-DOTA-Octreotide PET/CT scanning with a pa-
tient with malignant carcinoid tumor showing multiple lymph node 
metastases as well as large liver metastases. 
 
18F -Fluorodeoxyglucose  PET  (18F-FDG  PET)  is 
increasingly being used for various malignant tumors. 
18F-FDG  is  useful  for  evaluating  tumor  hexokinase 
activity, which is increased in tumor cells because of 
the  accelerated  rate  of  glycolysis.  18F-FDG  PET  is 
primarily used in tumors for the purpose of diagnosis, 
staging, restaging and evaluation of the response to 
treatment. The main use of 18F-FDG-PET in diagnosis 
of  NETs  depends  on  the  grade  of  differentiation 
and/or aggressiveness of NETs.[16-18]  18F-FDG PET 
is more sensitive than SRS in picking up less differen-
tiated GEP-tumors (G3) but is less sensitive than SRS 
in  detection  of  well  differentiated  GEP-tumors 
(G1/G2) (Figure 3). In a recent study 98 prospectively 
enrolled patients with NETs underwent 18F-FDG PET 
imaging.[19] The study showed a strong prognostic 
value  of  18F-FDG  PET  for  NETs  which  exceeds  the 
prognostic value of traditional markers such as Ki-67, 
CgA and liver metastases. The diagnostic sensitivity 
of  18F-FDG  PET  was  58%.  A  positive  18F-FDG  PET 
result was associated with a significantly higher risk 
of death with a hazard ratio (HR) of 10.3 [95% confi-
dence interval (CI) 1.3-78-9]. A high standard uptake 
value (SUV) is indicating a more aggressive disease 
and SUV-max of >3 was the only predictor of shorter 
progression free survival (p=0.001). However, in spite 
of these successful results in NETs, one major limita-
tion  of  18F-FDG  as  a  tumor  marker  is  that  it  is  not 
completely specific for tumor.  18F-FDG is known to 
accumulate in inflammatory lesions also thereby in-
creasing the false positivity rate.[13]  
NETs are known to accumulate and decarbox-
ylate,  5’-hydrozytryptamine  and 
l-3,4-dihydroxyphenylalanine (l-DOPA). An increase 
in the activity of l-DOPA decarboxylase is one of the 
hallmarks of NETs.[20] The first study that demon-
strated  the  utility  of  11C-DOPA  in  the  detection  of 
pancreatic  tumor  was  conducted  by  our  group  in 
1995.[21]  18F-DOPA  PET  has  also  been  found  to  be 
useful in advanced NET.[22] The potential limitation 
of  18F-DOPA PET is normally high accumulation in 
the  duodenum  and  pancreas,  which  might  cause 
problems in localisation of tumors in the region. An-
other  important  tracer  for  NETs  is 
11C-hydroxytroyptophan PET (11C-5HTP PET), which 
is  based  on  the  uptake  11C-hydroxytryoptophan  by 
neuroendocrine cells, decarboxylated and then stored 
in vesicles as  11C-5HT. PET scanning with  11C-5HTP 
visualises significantly more lesions than SRS, CT or 
MRI  in  patients  with  NETs.[23]  The  sensitivity  of 
11C-5HTP PET is almost 90% and can detect tumors as 
small as 3 mm (Figure 4 and 5). It has been observed 
that  11C-5HTP PET can be used in patients without 
elevated 5HT synthesis and it appears to be a univer-Theranostics 2012, 2(5) 
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sal tracer for neuroendocrine tumors irrespective of 
origin and can visualise more than 90% of all types of 
NETs  including  endocrine  pancreatic  tumors.[24] 
Furthermore, the possibility to modulate the uptake of 
11C-5HTP  with  carbidopa  has  facilitated  the  perfor-
mance of whole-body PET.[16, 23] Importantly poorly 
differentiated tumor  with  little or  no  hormone pro-
duction  (G3-tumors)  can  be  falsely  negative  with 
11C-5HTP  or  18F-DOPA  PET.  The  tracer 
11C-hydroxyefedrin  (Figure  6)  has  been  explored  in 
patients  with  pheochromocytoma. 
11C-hydroxyefedrin  has  been  applied  in  studies  of 
pheochromocytoma  presenting  a  sensitivity  and 
specificity of 90-100%. Other potential receptors to be 
targeted for diagnosis and therapy are listed in table 
2.[25]  
 
 
Figure 3. FDG/PET of a patient with a high-grade neuroendocrine tumor (G3 tumor) with bone metastases as well as lymph node and 
liver metastases.  
 
Figure 4. 11C-5HTP PET/CT of a patient with a small intestinal neuroendocrine tumor (carcinoid) which was considered to be cured after 
surgery. A small lymph node, <1cm, showed abnormal tracer accumulation demonstrating a lymph node metastasis.  Theranostics 2012, 2(5) 
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Figure 5.  11C-5HTP scanning of a patient with midgut carcinoid tumor showing bone metastases that was not detected by standard 
radiology such as CT or MRI. 
 
 
 
Figure 6. PET scanning with 11C-metomidate and 11C-hydroxyefedrine as tracers in a patient with a 2 cm incidentaloma of the adrenal 
gland. The tumor is accumulating 11C hydroxyefedrin indicating a pheochromocytoma, not an adrenocortical tumor. Theranostics 2012, 2(5) 
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Table 2. Potential Receptors Other Than SS Receptors for Clinical Use  
Peptide  Receptor Subtypes  Tumor Expression  Radiolabeled Peptides 
Bombesin/GRP  GRP-R  Prostate cancer, breast cancer, GISTs, SCLC  99mTc-bombesin 
111ln-bombesin, 68Ga-bombesin 
CCK/gastrin  CCK2  MTC, insulinoma, SCLC, GISTs  111In-DTPA-minigastrin 
      99Y-minigastrin 
GLP-1  GLP-1-R  Insulinoma, gastrinoma  123I-GLP-1 
Neuropeptide-Y  NPY-R  Breast cancer, ovarian and adrenal tumors  99mTc-neuropeptide Y 
Neurotensin  NT-R1  Exocrine pancreatic cancer, Ewing sarcoma, meningioma  99mTc-neurotensin 
Substance P  NK1  Glial tumors  90Y-DOTAGA-Substance P 
VIP  VPAC1  Gastro-intestinal and other epithelial cancers  123I-VIP 
99mTc-TP3654 
GRP-R, gastrin releasing peptide–receptor; CCK, cholecystokinin; GLP, glucagon-like peptide; VIP, vasoactive intestinal peptide; 
VPAC, VIP–pituitary adenylate cyclase-activating polypeptide; NK, neurokinin; GISTs, gastrointestinal stromal tumors.  
Adapted from Rufini et al. Semin Nucl Med 36:228-247 
 
Summary 
Nuclear  imaging  techniques  have  significantly 
improved  the  localisation  and  staging  of  NETs.  Be-
sides  anatomical  localisation  they  also  give  infor-
mation  about  metabolism,  receptor  expression  and 
the distribution of drugs. PET imaging for tumor lo-
calisation and follow-up of treatment is more or less 
established in different types of endocrine tumors. In 
the future PET may enable the in-vivo determination 
of  the  proliferation  and  an  alteration  in 
gene-expression  during  treatment.  Another  advan-
taged of PET is the response to new therapies such as 
angiogenesis  and  tyrosine  kinase  inhibitors,  which 
can be rapidly detected. Although the PET scanning is 
expensive it is cost effective because patients not re-
sponding  to  therapy  do  not  need  to  continue  with 
these expensive drugs.  
Peptide-receptor Radionuclide Therapy 
(PRRT) 
In the 1990s peptide receptor radionuclide ther-
apy  (PRRT)  with  radiolabeled  somatostatin  analogs 
was introduced as promising treatment modality for 
patients with inoperable or metastasized NETs. Given 
the  ability  of  radiolabeled  somatostatin  analogs  to 
identify somatostatin receptor positive tumor the next 
logical step was to try and use radiolabeled somato-
statin analogs as a novel treatment for this group of 
tumors. Radiolabeled somatostatin analogs generally 
comprise  three  main  parts  the  cyclic  octapeptide 
(e.g.Tyr3-octreotide or Tyr3-octreotate) a chelator [e.g. 
DTPA  or  teraazacyclododecane  tetraacetic  acid 
(DOTA)]  and  a  radioactive  element.  Radioisotopes 
commonly used in PRRT are 111In, 90Y and 177Lu.  
111In-DTPA octreotide  
Studies  in  the  early  1990s  used  the  Au-
ger-electron-emitting 111In-DTPA-octreotide for PRRT 
as  somatostatin  analogs  labeled  with  β-emitting  ra-
dionuclides were not available for clinical use at that 
time.  Treatment  with  high  doses  of 
111In-DTPA-octreotide often led to symptomatic relief 
in  patients  with  metastatic  NETs;  However,  tumor 
shrinkage  was  rarely  achieved.[26-28]  The  most 
common  long-term  adverse  effects  of 
111In-DTPA-octreotide  therapy  resulted  from  toxic 
effects  to  the  bone  marrow.  Serious  adverse  effects 
included leukemia and myelodysplastic syndrome in 
three patients who had been treated with total cumu-
lative doses of >100 GBq and in whom bone-marrow 
radiation doses were estimated at >3 Gy. Delpassand 
et  al  treated  32  patients  with  high  doses  of 
111In-DTPA-octreotide, 18 of whom received two cy-
cles of 18.5 GBq. Of the 18 patients treated with two 
cycles, 16 had stable disease and two had partial re-
mission; median time to progression was not report-
ed.[29]  
90Y-DOTATOC 
The next generation of radionuclide therapy that 
targeted somatostatin receptors was the radiolabeled, 
modified  somatostatin  analog  90Y-DOTA, 
Tyr3-octreotide (90Y-DOTATOC). As a consequence of 
the replacement of phenylalanine by tyrosine as the 
third amino acid in the octapeptide, this analog has 
increased the affinity for somatostatin receptor sub-
type 2. The Basel group have used protocol with ad-
ministration of a cumulative dose of 7.4 GBq/m2 in 
two cycles and showed partial remission in 7-28% of 
the  patients  and  stable  disease  in  50%  up  to Theranostics 2012, 2(5) 
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80%.[30-32] The responses were higher in pancreatic 
endocrine tumors than in carcinoid tumors. Dosimet-
ric  and  dose-escalating  phase  I  studies  of 
90Y-DOTATOC have been performed in Milan, Italy, 
both  with  and  without  the  administration  of  re-
nal-protecting  agents.[33]  Doses  up  to  5.6  GBq  per 
cycle were administered. Responses were reported to 
be partial remission in about 29% of the patients. In a 
multicenter, phase I trial with  90Y-DOTATOC 60 pa-
tients  received  escalating  doses  of  radioactivity 
without reaching the maximum tolerated single dose. 
The  cumulative  radiation  dose  to  the  kidneys  was 
limited  to  27  Gy.  Concomitant  amino-acid  infusion 
was performed. Partial remission was obtained in 30% 
and stable disease in 50%.[34] In a large international 
multicenter trial 90Y-edotreotide was administered of 
3 cycles of 4.4 GBq in 90 patients, 75% showed stable 
disease  or  response.[35]  Recently  response,  survival 
and long-term toxicity was evaluated after treatment 
with 90Y DOTATOC in 1.109 NET patients. Objective 
response  was  noted  in  34%,  median  survival  44.7 
months over all 12% haematological grade 3/4 tox-
icity was found and 9% grade 3/4 renal toxicity.[36]  
177Lu-DOTATATE 
177Lu-DOTA, Tyr3-octreotate represents the third 
generation  of  somatostatin  receptor  targeted  radio-
nuclide therapies and has been used in several hos-
pitals since the beginning of year 2000. The only dif-
ference  between  DOTA,  Tyr3-octreotate  and  DOTA, 
Tyr3-octreotide  is  that  the  C-terminal  threoninol  of 
DOTA,  Tyr3-octreotide  is  replaced  with  the  amino 
acid,  threonine.  As  a  result,  DOTATATE  displays 
improved  binding  to  somatostatin  receptor  positive 
tissues  when  compared  with  DOTATOC.  Gastroen-
teropancreatic tumors predominantly express subtype 
2 of the somatostatin receptor and DOTATATE has a 
six-fold to nine-fold increased affinity for this receptor 
subtype.[37,  38]  177Lu-labeled  somatostatin  analogs 
have  an  important  practical  advantage  over  their 
90Y-labeled counterparts: 177Lu is not a pure β emitter, 
but also emits low-energy γ rays, which allows direct 
post-therapy imaging and dosimetry.[39] In a study 
by Kwekkeboom and co-workers  177Lu therapy was 
applied in a large group of patients.[40] The patients 
received  up  to  an  intended  cumulative  radioactive 
dose of 22.2-29.6 GBq limiting the dose to the kidneys 
to 23 Gy. The treatment interval between the doses 
was 6-10 weeks applying 4 courses in most patients. 
504 patients were treated according to the study pro-
tocol. Adverse effects within the first 24 hours were 
nausea  in  25%  of  administrations,  vomiting  in  10% 
and  pain  in  10%.  Haematological  adverse  effects 
(WHO grades 3 or 4) occurred in 3.6%. Mild and re-
versible alopecia was reported by 62% of the patients. 
Serous, delayed adverse effects occurred in 9 patients 
of whom 2 had decline in kidney function and 1 pa-
tient developed renal insufficiency 1.5 years after re-
ceiving her last treatment. Liver toxic effects occurred 
in 3 patients who had very extensive hepatic metas-
tases. Tumors size was evaluated in 310 patients and 
partial response was obtained in 28 %, stable disease 
in 51%, and progressive disease in 20%. Median time 
to  progression  was  40  months.  Median  overall  sur-
vival after initiation of treatment was 46 months. The 
most  important  predictive  factor  for  survival  was 
treatment  outcome  progression  versus 
non-progressive disease. Other predictive factors in-
cluded  extent  of  liver  metastases,  a  low  Karnofsky 
performance status score, baseline weight loss, and to 
a lesser degree presence of bone metastases. A sur-
vival benefit for patients treated with 177Lu-octreotate 
was  23-69  months  in  comparisons  with  historical 
controls. Quality of life was also evaluated in 50 pa-
tients using the Cancer Quality-of-Life Questionnaire 
C30. Global health status and quality of life markedly 
improved after therapy with 177Lu-octreotate.[41] Our 
group has treated 300 patients with the same protocol 
as the Rotterdam group with similar response rates 
(OR  42%).  Patients  with  rectal  carcinoids  show  the 
best responses (Figure 8). 
 
Other Radiolabeled Somatostatin Analogs 
Lanreotide can be labeled with 111In for diagnos-
tic and therapeutic purposes and with  90Y for thera-
peutic  use.[42]  Use  of  radiolabeled  lanreotide  has 
been advocated because of its increased affinity for 
somatostatin  receptor  subtypes  3  and  4  when  com-
pared  with  111In-octreotide,  but  this  claim  is  ques-
tionable.[37]  Although  radiolabeled  lanreotide  has 
been used to treat patients with NETs the affinity of 
this agent is less than that of radiolabeled DOTATOC 
or  Octreotate  for  somatostatin  receptor  subtype  2, 
which is over-expressed in this class of tumors.[38] 
DOTANOC is a peptide in which the third ami-
no acid of octreotide (phenylalanine) is replaced by 
1-naphthylalanine. DOTANOC has a good affinity for 
somatostatin  receptor  subtypes  2,  3  and  5  which 
might be important for imaging and treatment of tu-
mors with atypical expression of these receptor sub-
types.[43, 44] 
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Figure 7. Graphic presentation of 177Lutetium-DOTA, Tyr3-octreotate. 
 
 
 
Figure 8. Treatment with 177Lutetium-DOTA, Tyr3-octreotate in a patient with rectal carcinoid demonstrating effect of treatment over 
time. 
 
 
Summary 
PRRT with radiolabeled somatostatin analogs is 
a  promising  new  option  for  these  individuals  pro-
vided that tumoral uptake of these agents is adequate 
on  pre-treatment  SRS  (grade  3  and  grade  4).  Treat-
ment  with  any  of  the  various  labeled  somatostatin 
analogs can result in symptomatic improvement but 
reduction of tumor size is seldom achieved with In-
dium-labeled  somatostatin  analogs.  Large  variation 
exists  in  the  reported  anti-tumor  effect  of 
90Y-DOTATOC between various studies. But an  ob-
jective  response  was  achieved  in  9-33%  of  patients. 
177Lu-DOTATATE  objective  responses  have  been 
achieved in about 40% of patients; stable disease was 
present in 35-50%. Adverse effects of PRRT are few 
and  mostly  mild,  certainly  when  renal-protective 
agents are used. Serious, delayed adverse effects such 
as myelodysplastic syndrome, renal failure or leuke-
mia are noted. The median duration of responses to Theranostics 2012, 2(5) 
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therapy with 90Y-DOTATOC and 177Lu-DOTATATE is 
30  months  and  40  months,  respectively.  Large  ran-
domized clinical trials of PRRT are still needed. An-
other item which has to be evaluated is the value of 
dosimetry. Nevertheless, PRRT might soon become an 
important therapy for patients with metastatic or in-
operable GEP-NETs.[45] 
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